Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), T. Maher (London, United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), V. Kohlbrenner (Ridgefield, Connecticut , United States of America), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), O. Distler (Zurich, Switzerland)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), T. Maher (London, United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), V. Kohlbrenner (Ridgefield, Connecticut , United States of America), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), O. Distler (Zurich, Switzerland). Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD). 4731
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: